AI assistant
MEMPHASYS LIMITED. — Capital/Financing Update 2019
Mar 27, 2019
65314_rns_2019-03-27_6a04ec97-8dda-4d81-b3d7-e410fa1c8701.pdf
Capital/Financing Update
Open in viewerOpens in your device viewer
==> picture [222 x 64] intentionally omitted <==
ASX Release 28 March 2019
Rights Issue Prospectus Completion
Pursuant to the Non-renounceable Rights Issue Prospectus dated 28 February 2019 and lodged with ASIC and ASX on same day, the following securities have been allotted today:
Shares issued to applicants: Additional shares applied for and issued to applicants: Shortfall allotment:
88,508,701 6,228,073 87,307,799
Total allotment of shares:
Total shares on issue after allotment:
182,044,573 546,133,718
For further information please contact:
Alison Coutts Executive Chairman Memphasys Limited +61 2 8415 7300 [email protected]
David Tasker Managing Director Chapter One Advisors +0433 112 936 [email protected]
About Memphasys:
Memphasys Limited (ASX: MEM) specialises in biological separations for high value commercial applications. The Company’s patented membrane processes in combination with electrophoresis, the application of an electrical potential difference across a fluid, enable the separation of high value substances or contaminants from the fluid in which they are contained.
The main application of the technology is the separation of the most viable sperm cells for artificial reproduction, most particularly for human IVF.
Postal Address Contact Details E [email protected] P.O. Box 2202 P +612 8415 7300 W memphasys.com Homebush West NSW 2140 F +612 8415 7399 ABN 33 120 047 556
Memphasys Limited 30-32 Richmond Road Homebush West NSW 2140